Home LiteratureArticle Details
PMID: 10858406 Published · ppublish English Journal Article

Preoperative and postoperative endotoxemia in children with congenital heart disease.

Chest ·Vol. 117 ·No. 6 ·2000-06-00 ·Pages 1706-12

Lequier LL, Nikaidoh H, Leonard SR, Bokovoy JL, White ML, Scannon PJ, Giroir BP

Abstract

Recent data indicate that increases in inflammatory cytokines are seen in patients with diverse cardiac diseases. However, the primary stimulus for cytokine secretion during cardiac illness remains unknown. Since bacterial endotoxin is a potent inducer of cytokines, we determined the incidence, magnitude, and clinical relevance of endotoxemia in children with congenital heart disease before and after surgical repair. A prospective, observational study. A large, urban, university-affiliated, tertiary-care children's hospital. Thirty children with a variety of congenital heart defects (median age, 59 days; median weight, 4.0 kg) were sequentially enrolled. Blood was sampled prior to surgery, and at 1, 8, 24, 48, and 72 h following cardiopulmonary bypass. Assays included plasma endotoxin, lipopolysaccharide-binding protein (LBP), and interleukin-6 (IL-6). Twenty-nine of 30 patients (96%) had evidence of endotoxemia during the study period. Twelve of the 30 patients (40%) were significantly endotoxemic prior to surgery. LBP, a plasma marker that responds to bacteria and endotoxin, rose significantly following cardiopulmonary bypass, as did the plasma levels of IL-6. Fifteen of 30 patients met prospectively defined criteria for experiencing a severe hemodynamic disturbance in their postoperative course. These patients had significantly higher preoperative plasma LBP (p < 0.02) and plasma endotoxin levels (p < 0.05), compared to patients with less-severely disturbed hemodynamics. Mortality was 25% in patients with preoperative endotoxemia, compared with no mortality in patients who were not endotoxemic before surgery (p = 0.05). These data demonstrate that endotoxemia in children with congenital heart disease is more common than previously suspected, and is associated with clinical outcomes. We conclude that clinical trials targeting endotoxin will be necessary to determine if endotoxin is a causal, etiologic agent in the disease process.

MeSH Terms
Acute-Phase Proteins Cardiopulmonary Bypass Carrier Proteins/blood Cytokines/blood Endotoxemia/diagnosis,immunology,mortality Endotoxins/blood Female Heart Defects, Congenital/immunology,mortality,surgery Hemodynamics/physiology Humans Infant Interleukin-6/blood Male Membrane Glycoproteins Postoperative Complications/diagnosis,immunology,mortality Prognosis Prospective Studies Survival Rate
Chemicals
Acute-Phase Proteins Carrier Proteins Cytokines Endotoxins Interleukin-6 Membrane Glycoproteins lipopolysaccharide-binding protein
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Lequier L L
Department of Pediatrics,The University of Texas Southwestern Medical Center, Dallas 75235-9063, USA.
Nikaidoh H
Leonard S R
Bokovoy J L
White M L
Scannon P J
Giroir B P
Article Info
Journal
Chest
Abbr.
Chest
ISSN
0012-3692
Published
2000-06-00
Pages
1706-12
Language
English
Region
United States
NLM ID
0231335
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com